CGRP-provoked headache is associated with a neuroimmune signature in idiopathic intracranial hypertension

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in this randomized controlled trial publication.

Idiopathic intracranial hypertension (IIH) is characterised by raised intracranial pressure and disabling headaches, yet its underlying mechanisms remain poorly defined.

Calcitonin gene-related peptide (CGRP) is a key neuropeptide implicated in migraine and headache attributed to IIH.

Who Took Part

The abstract describes 16 women taking part.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, women only.

CGRP induced a typical IIH headache attack within the sampling period in 7/16 participants.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received CGRP (Calcitonin Gene-Related Peptide).

A placebo (an inactive look-alike) gave the CGRP (Calcitonin Gene-Related Peptide) group a baseline to be compared against.

In the crossover set-up each of the women took both CGRP (Calcitonin Gene-Related Peptide) and the comparison in turn, acting as their own control.

Blood samples were collected at baseline and either at peak headache or at the end of the visit, if no headache occurred.

Plasma cytokines were measured using the Olink® Target 48 Cytokine Panel.

What Was Measured

The subject headings attached to it are Calcitonin Gene-Related Peptide, Cytokines, Pseudotumor Cerebri and Headache.

The authors tagged it with the keywords Calcitonin gene-related peptide (CGRP), IIH headache, Idiopathic intracranial hypertension and Neuroinflammation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in 16 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The journal of headache and pain), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.